We advised the sales agent on the offering

Davis Polk advised the sales agent in connection with the SEC-registered at-the-market offering by AN2 Therapeutics, Inc. of its common stock for up to an aggregate amount of $80 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “ANTX.”

Based in Menlo Park, California, AN2 Therapeutics is a clinical stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from its boron chemistry platform. Its development pipeline spans hematologic diseases, infectious diseases and oncology, as well as advanced research programs focused on targets in oncology, bone disorders and infectious diseases.

The Davis Polk corporate team included partner Emily Roberts and associates Jared Madnick and Grace Yongxi Pan. All members of the Davis Polk team are based in the Northern California office.

Copy link to share post